MedTrace Logo

Thalidomide in the Treatment of Chronic Plaque Psoriasis.

NCT01891019 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2018-08-13

No results posted yet for this study

Summary

The objective of this study is to obtain information on the effectiveness of thalidomide in psoriasis.

Conditions

  • Psoriasis, Plaque-type

Interventions

DRUG

Thalidomide oral

Thalidomide will be administered nightly, with each subject taking 2 capsules totaling 100 milligrams for the initial two weeks of treatment, 3 capsules totaling 150 milligrams for week 2 to week 4, and 4 capsules totaling 200 milligrams for week 4 to end of treatment. The subjects will take the medication for 12 weeks.

Sponsors & Collaborators

  • Wake Forest University

    lead OTHER

Principal Investigators

  • Steve Feldman, MD, PhD · Wake Forest University Health Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Primary Completion
2005-09-30
Completion
2009-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01891019 on ClinicalTrials.gov